Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Last trade$13.39
Day change-$0.415 (-3.01%)
Day range$13.21 – $14.02
Volume797,143
Market cap$2.08B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.08B
Price / earnings
—
Price / book
-21.22×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.37×
Profitability
Earnings per share
-$3.59
Return on assets
-205.81%
Return on equity
552.36%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-2.69×
Current ratio
3.05×
Quick ratio
3.05×
Cash ratio
1.53×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$473.17M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BHVN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$24.57M
$24.09M
$26.6M
$20.79M
$28.21M
$27.33M
$33.98M
$22.46M
Research and development
$101.85M
$100.81M
$103.83M
$121.95M
$141.17M
$184.37M
$187.58M
$167.47M
Total operating expenses
$126.42M
$124.9M
$130.43M
$142.73M
$169.38M
$211.7M
$221.56M
$189.93M
Operating income
-$126.42M
-$124.9M
-$130.43M
-$142.73M
-$169.38M
-$211.7M
-$221.56M
-$189.93M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$129.34M
-$136.92M
-$130.26M
-$145.2M
-$173.22M
-$197.89M
-$221.07M
-$186.8M
Income taxes
-$64K
$391K
$272K
$351K
$221K
$261K
$609K
$48K
Net income
-$129.28M
-$137.31M
-$130.53M
-$145.56M
-$173.44M
-$198.15M
-$221.68M
-$186.84M
Net income attributable to common shareholders
-$129.28M
-$137.31M
-$130.53M
-$145.56M
-$173.44M
-$198.15M
-$221.68M
-$186.84M
EBITDA
-$124.2M
-$122.64M
-$128.06M
-$140.16M
-$166.26M
-$209.72M
-$219.32M
-$187.47M
Basic earnings per share
-$0.86
-$0.91
-$0.88
-$1.21
-$1.64
-$1.94
-$2.17
-$1.85
Diluted earnings per share
-$0.86
-$0.91
-$0.88
-$1.21
-$1.64
-$1.94
-$2.17
-$1.85
Recent news
Company coverage with links to the original publishers.
Bexorg, a precision neurology company, received up to $28.3 million in funding from ARPA-H to extend its BrainEx perfusion technology from 24 hours to two weeks. This advancement will enable longitudinal studies of human brain pharmacology and drug responses, potentially reducing CNS drug development attrition by providing richer human brain data for AI model training and clinical trial design.
Biohaven announced a licensing and collaboration deal with SK Biopharmaceuticals worth up to $795 million for exclusive worldwide rights to its Kv7 ion channel platform and lead drug candidate opakalim for focal epilepsy treatment. Additionally, Biohaven and Yale University won a $4 million judgment in a trade secret misappropriation lawsuit against Avilar Therapeutics and RA Capital Management. These developments drove Biohaven stock up more than 16% week-to-date.
Sarissa Capital Management established a new $5.79 million position in clinical-stage biotech Biohaven, acquiring 513,184 shares during Q4 2025. Despite the stock falling 70% over the past year due to FDA rejection of troriluzole and disappointing trial results, the fund's investment signals potential turnaround prospects. Biohaven has refocused on late-stage programs including a degrader platform and Phase 2 obesity candidate with data expected in H2 2026, while maintaining a strengthened balance sheet with $500.9 million in cash.
Biohaven shares surged 6.65% in regular trading and 3.42% in after-hours trading following an investor presentation at the J.P. Morgan Healthcare Conference. The company presented Phase 1 data for BHV-1400 showing significant reductions in IgA nephropathy markers and clinical improvements in patients. Multiple catalysts are expected in 2026, including Phase 2 obesity trial results, pivotal epilepsy trial results, and initiation of trials for other candidates. However, the stock has declined 67.11% over the past 12 months and is trading near its 52-week lows.
U.S. stock futures declined on Friday following Wednesday's gains, with major indices showing modest losses. Key movers included Nvidia rising on a licensing agreement with Groq, Dynavax surging 38% on Sanofi acquisition news, Sobr Safe dropping 16% after announcing a private placement, and Biohaven plummeting 14% after a failed clinical trial. Economist Justin Wolfers cautioned that U.S. market gains are lagging global markets significantly.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.